Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q1 2021 · 10-Q
Revenue$360.07M$360.07M+1.6% vs Q1 2020 Net Income$45.39M$45.39M+394.5% vs Q1 2020 EPS Diluted$0.53$0.53+381.8% vs Q1 2020 Operating Income$30,714,000+13.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
Free Cash Flowderived$62,406,000+1,353.0% Margins · derivedOperating margin8.5%+0.9 pt vs Q1 2020
Net margin12.6%+10.0 pt vs Q1 2020
ended Mar 31, 2021 · filed Apr 29, 2021 · 29 d after period end